Patient safety advanced by revised heparin standards

July 30, 2009

Rockville, Md., July 30, 2009 -- Continuing to help ensure the identity, purity and quality of heparin, the U.S. Pharmacopeial (USP) Convention has revised written and physical standards for the widely used blood thinner. In February, USP released updated heparin standards at the request of the Food and Drug Administration (FDA) in response to the 2008 public health crisis in which more than 200 people died as a result of heparin adulterated for economic gain. A second phase of revisions is reflected in the newly posted standards. These developments and new information about heparin were discussed by scientists and regulators at the third International Heparin Workshop held at USP headquarters in Rockville, Maryland, July 27󈞈.

"While financially-motivated adulteration of medicines is a distressingly persistent problem," noted Roger L. Williams, M.D., USP's chief executive officer, "I'm pleased at the progress we've made in helping to ensure that such tragic events are minimized. Stronger methods for detecting a range of potential contaminants have been thoroughly assessed and incorporated into the new test methods, and the new physical reference standards are specific to these methods. Manufacturers--and in consequence, physicians and their patients--can feel more confident of the purity and integrity of their heparin products."

The Workshop, co-sponsored by USP, the British National Institute of Biological Standards and Control (NIBSC), and the European Directorate for the Quality of Medicines (EDQM), reflected the global nature of both the problem of adulteration and the resources cooperating to combat it, with attendees from more than 17 countries.

The updated written standards are the Heparin Sodium Stage 2 Monograph and the Heparin Sodium Injection Stage 2 Monograph; new reference standards are Heparin Sodium for Assays, Oversulfated Chondroitin Sulfate, and Dermatan Sulfate. These and other related standards and information are available at http://www.usp.org/hottopics/heparin.html. The new standards will become official on October 1, 2009.
-end-
USP--Advancing Public Health Since 1820

The United States Pharmacopeial (USP) Convention is a scientific, nonprofit, standards-setting organization that advances public health through public standards and related programs that help ensure the quality, safety, and benefit of medicines and foods. USP's standards are recognized and used worldwide. For more information about USP visit http://www.usp.org.

US Pharmacopeia

Related Heparin Articles from Brightsurf:

UC San Diego researchers move closer to producing heparin in the lab
In a new study published in PNAS, UC San Diego researchers moved one step closer to the ability to make heparin in cultured cells.

Rivaroxaban superior to heparin in preventing blood clots after common orthopedic surgeries
The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Hitting HIT: Heparin therapy
Heparin is widely used as an anticoagulant, but evokes in some patients a potentially life-threatening condition called HIT.

URI chemistry professor develops contaminant detection technique for heparin
In 2008, a contaminant eluded the quality safeguards in the pharmaceutical industry and infiltrated a large portion of the supply of the popular blood thinner heparin, sickening hundreds and killing about 100 in the US.

Synthetic version of popular anticoagulant poised for clinical trials
A synthetic version of low molecular weight heparin is poised for clinical trials and development as a drug for patients with clotting disorders, and those undergoing procedures such as kidney dialysis, heart bypass surgery, stent implantation, and knee and hip replacement.

Heparin stimulates food intake and body weight gain in mice
Research shows that heparin, which is well known for its role as an anticoagulant, can also promote food intake and body weight increase in animal models.

Apixaban lowers stroke risk in AF patients undergoing cardioversion (EMANATE)
Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented today in a Hot Line LBCT Session at ESC Congress.

No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study today in JACC: Cardiovascular Interventions.

Smart patch releases blood thinners as needed
An interdisciplinary team of researchers has developed a smart patch designed to monitor a patient's blood and release blood-thinning drugs as needed to prevent the occurrence of dangerous blood clots.

Two differing medications used during heart procedure are both safe and effective, study finds
Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention, a non-surgical procedure to open blood vessels narrowed by plaque buildup, according to a new study.

Read More: Heparin News and Heparin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.